Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease
Leora Horn, MD, of Vanderbilt University, discusses phase III results from the eXalt3 trial, which suggest that ensartinib, a novel, next-generation ALK inhibitor, is superior to crizotinib in terms of progression-free survival as well as efficacy in central nervous system metastases for patients with ALK-positive non–small cell lung cancer (Abstract 2).